LENZ Therapeutics (LENZ) TD Cowen 46th Annual Health Care Conference summary

Launch overview and early performance

• Launched a once-daily presbyopia eye drop in October after August approval, targeting replacement of reading glasses.

• Product efficacy is strongly supported by both clinical and real-world data, with up to 10 hours of near vision improvement reported.

• Sampling strategy distributed five-day sample packs to 15,000 target doctors, driving patient trials and early adoption.

• Growing patient and doctor bases, with over 6,500 prescribing doctors as of January and rapid expansion since.

• Expansion of sales force underway to meet increasing demand and broaden reach beyond initial target group.

Market feedback and efficacy

• Strong positive feedback from both doctors and patients, with many reporting longer efficacy than the labeled 10 hours.

• Product works quickly, with noticeable effects within 15–30 minutes, and is effective across a broad presbyope population.

• Early refill data and patient stickiness are encouraging, with many moving from single to multi-pack purchases.

• Repeat prescribers report the product helps build their practices and does not cannibalize glasses sales.

Safety, tolerability, and clinician education

• Most side effects are mild and transient, such as brief hyperemia and rare headaches, with symptoms diminishing after a few days.

• Only one reported case of retinal tear, in a patient with prior retinal issues; no impact on prescribing trends observed.

• KOLs and clinicians generally do not view retinal safety as a concern for this product compared to others in the class.

• Sales force and clinician selection focus on expectation setting and patient safety, including recommending retinal exams.